Lisy Wang

2.6k total citations · 2 hit papers
40 papers, 2.0k citations indexed

About

Lisy Wang is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, Lisy Wang has authored 40 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Rheumatology, 19 papers in Hematology and 11 papers in Genetics. Recurrent topics in Lisy Wang's work include Rheumatoid Arthritis Research and Therapies (31 papers), Autoimmune and Inflammatory Disorders Research (19 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Lisy Wang is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (31 papers), Autoimmune and Inflammatory Disorders Research (19 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Lisy Wang collaborates with scholars based in United States, Germany and Canada. Lisy Wang's co-authors include Jeffrey R. Curtis, J. Wollenhaupt, Kenneth Kwok, Eun Bong Lee, Richard J. Riese, Koshika Soma, Stanley Cohen, Ryan DeMasi, Yoshiya Tanaka and Kevin Winthrop and has published in prestigious journals such as Gastroenterology, Annals of the Rheumatic Diseases and Journal of Investigative Dermatology.

In The Last Decade

Lisy Wang

39 papers receiving 1.9k citations

Hit Papers

Long-term safety of tofacitinib for the treatment of rheu... 2017 2026 2020 2023 2017 2021 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
    2017 302 citations Stanley Cohen, Yoshiya Tanaka et al. Annals of the Rheumatic Diseases profile →
  2. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
    2021 159 citations Atul Deodhar, Huji Xu et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisy Wang United States 17 1.3k 676 459 421 332 40 2.0k
Koshika Soma United States 15 1.4k 1.1× 704 1.0× 442 1.0× 441 1.0× 386 1.2× 24 2.0k
Chantal Tasset Belgium 19 1.4k 1.0× 711 1.1× 681 1.5× 644 1.5× 492 1.5× 72 2.3k
Birgitta Benda Sweden 12 1.2k 0.9× 659 1.0× 421 0.9× 395 0.9× 399 1.2× 22 1.8k
Pille Harrison United Kingdom 19 1.0k 0.8× 413 0.6× 662 1.4× 429 1.0× 359 1.1× 53 2.0k
Mikaël Ebbo France 23 674 0.5× 548 0.8× 741 1.6× 216 0.5× 224 0.7× 104 2.2k
Serena Bugatti Italy 28 1.3k 1.0× 301 0.4× 655 1.4× 289 0.7× 244 0.7× 89 2.1k
Xavier Mariette France 13 671 0.5× 310 0.5× 554 1.2× 138 0.3× 284 0.9× 40 1.7k
G. M. Bartelds Netherlands 13 978 0.7× 334 0.5× 1.0k 2.2× 106 0.3× 323 1.0× 15 1.9k
S. Kary Germany 19 1.6k 1.2× 668 1.0× 876 1.9× 70 0.2× 223 0.7× 23 2.2k
William Shergy United States 19 1.2k 0.9× 481 0.7× 561 1.2× 213 0.5× 300 0.9× 24 1.9k

Countries citing papers authored by Lisy Wang

Since Specialization
Citations

This map shows the geographic impact of Lisy Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisy Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisy Wang more than expected).

Fields of papers citing papers by Lisy Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisy Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisy Wang. The network helps show where Lisy Wang may publish in the future.

Co-authorship network of co-authors of Lisy Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Lisy Wang. A scholar is included among the top collaborators of Lisy Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisy Wang. Lisy Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ciurea, Adrian, Oliver Distler, Kenneth Kwok, et al.. (2023). Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start. Arthritis Research & Therapy. 25(1). 185–185. 4 indexed citations
2.
3.
Müeller, Ruediger B., Hendrik Schulze‐Koops, Daniel E. Furst, et al.. (2022). Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel). Clinical Rheumatology. 41(4). 1045–1055. 3 indexed citations
4.
Cella, David, William R. Lenderking, Andrew G. Bushmakin, et al.. (2022). Functional Assessment of Chronic Illness Therapy-Fatigue is a reliable and valid measure in patients with active ankylosing spondylitis. Journal of Patient-Reported Outcomes. 6(1). 100–100. 10 indexed citations
5.
Deodhar, Atul, Huji Xu, Xenofon Baraliakos, et al.. (2021). Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases. 80(8). 1004–1013. 159 indexed citations breakdown →
6.
Panaccione, Remo, John D. Isaacs, Lea Ann Chen, et al.. (2020). Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Digestive Diseases and Sciences. 66(9). 3214–3215. 1 indexed citations
7.
Cohen, Stanley, Yoshiya Tanaka, Xavier Mariette, et al.. (2020). Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 6(3). e001395–e001395. 135 indexed citations
8.
Panaccione, Remo, John D. Isaacs, Lea Ann Chen, et al.. (2020). Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Digestive Diseases and Sciences. 66(8). 2732–2743. 11 indexed citations
9.
Wollenhaupt, J., Jeffrey R. Curtis, Joel C. Silverfield, et al.. (2019). Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Research & Therapy. 21(1). 89–89. 238 indexed citations
10.
Cohen, Stanley, Yoshiya Tanaka, Xavier Mariette, et al.. (2018). Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program. Queensland's institutional digital repository (The University of Queensland). 70. 5 indexed citations
11.
Dikranian, Ara, Valderílio Feijó Azevedo, Louis Bessette, et al.. (2018). FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY. JCR Journal of Clinical Rheumatology. 25. 1 indexed citations
12.
Li, Zhanguo, Yi Liu, Huji Xu, et al.. (2018). Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis. Chinese Medical Journal. 131(22). 2683–2692. 27 indexed citations
13.
Fleischmann, Roy, J. Wollenhaupt, Stanley Cohen, et al.. (2018). Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatology and Therapy. 5(1). 203–214. 14 indexed citations
14.
Cohen, Stanley, Yoshiya Tanaka, Xavier Mariette, et al.. (2017). Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Annals of the Rheumatic Diseases. 76(7). 1253–1262. 302 indexed citations breakdown →
15.
Schulze‐Koops, Hendrik, Vibeke Strand, Chudy I. Nduaka, et al.. (2016). Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Lara D. Veeken. 56(1). 46–57. 69 indexed citations
16.
Genovese, Mark C., Ronald van Vollenhoven, Bethanie Wilkinson, et al.. (2016). Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. Arthritis Research & Therapy. 18(1). 145–145. 15 indexed citations
17.
Curtis, Jeffrey R., Eun Bong Lee, Irina V Kaplan, et al.. (2015). Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Annals of the Rheumatic Diseases. 75(5). 831–841. 125 indexed citations
18.
Wollenhaupt, J., Joel C. Silverfield, Eun Bong Lee, et al.. (2014). Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies. The Journal of Rheumatology. 41(5). 837–852. 253 indexed citations
19.
Borregaard, Jeanett, Lone Skov, Lisy Wang, et al.. (2008). Evaluation of the effect of the specific CCR1 antagonist CP‐481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects. Contact Dermatitis. 59(4). 212–219. 10 indexed citations
20.
Chada, Kiran, et al.. (1998). Epidermal Expression of Collagenase Delays Wound-Healing in Transgenic Mice. Journal of Investigative Dermatology. 111(6). 1029–1033. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Koshika Soma Breakdown of academic impact, for papers by Chantal Tasset Breakdown of academic impact, for papers by Birgitta Benda Breakdown of academic impact, for papers by Pille Harrison Breakdown of academic impact, for papers by Mikaël Ebbo Breakdown of academic impact, for papers by Serena Bugatti Breakdown of academic impact, for papers by Xavier Mariette Breakdown of academic impact, for papers by G. M. Bartelds Breakdown of academic impact, for papers by S. Kary Breakdown of academic impact, for papers by William Shergy
Rankless by CCL
2026